Oppenheimer Asset Management’s Pacira BioSciences PCRX Stock Holding History

Oppenheimer Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,579	Closed	-$391K	–	1152
2023 Q1	$391K	Buy	9,579 +944	+11%	+$37.6K	0.01%	903
2022 Q4	$333K	Sell	8,635 -3,968	-31%	-$193K	0.01%	941
2022 Q3	$670K	Sell	12,603 -1,338	-10%	-$74.4K	0.01%	765
2022 Q2	$813K	Sell	13,941 -5,413	-28%	-$355K	0.01%	730
2022 Q1	$1.48M	Sell	19,354 -690	-3%	-$46K	0.02%	630
2021 Q4	$1.21M	Sell	20,044 -1,237	-6%	-$68.2K	0.02%	721
2021 Q3	$1.19M	Buy	21,281 +1,844	+9%	+$106K	0.02%	689
2021 Q2	$1.18M	Buy	19,437 +3,521	+22%	+$223K	0.02%	698
2021 Q1	$1.12M	Buy	15,916 +3,302	+26%	+$236K	0.02%	688
2020 Q4	$755K	Buy	12,614 +4,949	+65%	+$290K	0.01%	775
2020 Q3	$461K	Buy	7,665 +3,060	+66%	+$178K	0.01%	836
2020 Q2	$242K	Buy	4,605 +3,114	+209%	+$130K	0.01%	985
2020 Q1	$50K	Buy	1,491 +897	+151%	+$37.3K	﹤0.01%	1262
2019 Q4	$27K	Sell	594 -123	-17%	-$5.22K	﹤0.01%	1421
2019 Q3	$27K	Sell	717 -7,049	-91%	-$281K	﹤0.01%	1426
2019 Q2	$338K	Sell	7,766 -175	-2%	-$7.43K	0.01%	925
2019 Q1	$302K	Buy	7,941 +188	+2%	+$7.34K	0.01%	937
2018 Q4	$333K	Sell	7,753 -1,410	-15%	-$65.8K	0.01%	867
2018 Q3	$450K	Sell	9,163 -98	-1%	-$4.24K	0.01%	848
2018 Q2	$297K	Sell	9,261 -2,601	-22%	-$89.8K	0.01%	950
2018 Q1	$370K	Buy	11,862 +4,487	+61%	+$160K	0.01%	865
2017 Q4	$277K	Hold	7,375	–	–	0.01%	950
2017 Q3	$277K	Buy	7,375 +4,976	+207%	+$200K	0.01%	954
2017 Q2	$114K	Buy	+2,399	New	+$111K	﹤0.01%	1161

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Oppenheimer Asset Management's PCRX Position: Q2 2023 in Review

Oppenheimer Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 9,579 shares — an estimated $391K sold.

Oppenheimer Asset Management first reported a position in PCRX in Q2 2017 and held it in 24 quarters. The position peaked at $1.48M in Q1 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Oppenheimer Asset Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Oppenheimer Asset Management sold 9,579 Pacira BioSciences shares in Q2 2023, an estimated $391K.
Oppenheimer Asset Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 24 quarters.
Oppenheimer Asset Management's Pacira BioSciences position peaked at $1.48M in Q1 2022.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Oppenheimer Asset Management's 13F filing for Q2 2023, filed 3 Aug 2023.